Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
List view / Grid view
Filter the results
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.